Breaking News, Financial News

Financial Report: Baxalta

Newly launched, independent company gains momentum

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Baxalta 2Q Revenues: $1.4 billion (-2%) 2Q Earnings: $272 million (-24%) YTD Revenues: $2.8 billion (flat) YTD Earnings: n/a Comments: Hematology revenues were $855 million, excluding the impact of foreign exchange, grew 6% in the quarter driven by ADVATE, a treatment for hemophilia A, and double-digit growth of FEIBA, an inhibitor treatment. Newly launched products also contributed to growth, including RIXUBIS for the treatment of hemophilia B, and OBIZUR for the treatment of acq...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters